文献速递腹部技术与安全US

一种新型纳米级相变造影剂通过靶向肝星状细胞血小板衍生生长因子β受体在体外用超声评估肝纤维化

A Novel Nanoscale Phase-Change Contrast Agent Evaluates the Hepatic Fibrosis Through Targeting Hepatic Stellate Cell Platelet-Derived Factor Beta Receptor by Ultrasound in Vitro.
PubMed 文献 · Ultrasound Med Biol · 2024-12-16

研究合成靶向PDGFRβ的纳米级相变造影剂(PPCAs),用于靶向活化的肝星状细胞(aHSC)并进行超声成像,以期为肝纤维化早期评估奠定基础。体外实验显示PPCAs平均直径283.6±11.3 nm、分散性和稳定性良好,在37°C、机械指数1.0的高频超声激发下具有良好生物相容性和成像能力,对aHSC的细胞摄取率达56.67±5.96%。

要点

  • PPCAs平均直径283.6±11.3 nm,分散性和稳定性良好。
  • 在37°C、机械指数1.0的高频超声激发下,PPCAs对aHSC的细胞摄取率达56.67±5.96%。
  • PPCAs有望通过靶向aHSC增强超声成像,为肝纤维化诊断奠定基础。

核心结论

  • PPCAs作为一种新的成像途径,具有良好生物相容性和稳定性,能特异性靶向aHSC,有潜力增强超声成像并为诊断奠定基础。

研究设计与样本

  • 体外研究,合成PDGFRβ抗体修饰的相变造影剂(PPCAs),采用薄膜水化和超声乳化法包裹全氟戊烷(PFP),用荧光共聚焦显微镜和流式细胞术评估靶向能力,并分析不同温度和机械指数下的相变及超声造影成像。

诊断标准与关键数值

  • PPCAs平均直径为283.6±11.3 nm,分散性良好且相对稳定。
  • 回波强度随机械指数增加而相应增加。
  • 在37°C、机械指数1.0的高频超声激发下,PPCAs表现出良好的生物相容性和成像能力。
  • PPCAs对aHSC的细胞摄取率达到56.67±5.96%,显示强的特异性靶向能力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: As a reversible condition at its early stages, liver fibrosis can progress to cirrhosis and hepatocellular carcinoma, underscoring the importance of early detection for preventing severe outcomes and improving prognosis. To address this issue, we developed a platelet-derived growth factor receptor β (PDGFRβ)-targeted nanoscale phase-change contrast agent to target activated hepatic stellate cells (aHSC) and enable ultrasound imaging as a foundation for the early evaluation of liver fibrosis.

METHODS: PDGFR-β antibody-modified phase-change contrast agents (PPCAs) were synthesized utilizing film hydration and ultrasonic emulsification with perfluoropentane (PFP) encapsulated. PPCAs were specifically conjugated to aHSC with high PDGFR-β expression, whose targeting ability was evaluated using fluorescence confocal microscopy and flow cytometry. Phase transition at different temperatures and mechanical indices (MIs), as well as contrast-enhanced ultrasound imaging were analyzed.

RESULTS: PPCAs had an average diameter of 283.6 ± 11.3 nm with good dispersibility and relative stability, and the echo intensity increased correspondingly with increasing MIs. PPCAs exhibited both excellent biocompatibility and imaging ability when excited by high-frequency ultrasound set to an MI of 1.0 at 37°C, and simultaneously showed strong specific targeting ability to aHSC, with cellular uptake reaching 56.67 ± 5.96%.

CONCLUSION: As a new imaging avenue, PPCAs have the potential to enhance ultrasound imaging and establish the basis for diagnosis by targeting aHSC specifically with good biocompatibility and stability.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Li HM, Feng LL, Jiang Q, et al. A Novel Nanoscale Phase-Change Contrast Agent Evaluates the Hepatic Fibrosis Through Targeting Hepatic Stellate Cell Platelet-Derived Factor Beta Receptor by Ultrasound in Vitro. Ultrasound Med Biol. 2024. PMID: 39690041. doi:10.1016/j.ultrasmedbio.2024.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。